News Conference News ACC 2025 Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE Caitlin E. Cox April 02, 2025
News Conference News ACC 2024 PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE L.A. McKeown April 08, 2024
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 ‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk Caitlin E. Cox March 10, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2021 Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions L.A. McKeown May 21, 2021
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News ACC 2018 Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis Michael O'Riordan March 14, 2018
News Conference News ACC 2018 ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit Michael O'Riordan March 10, 2018
News Conference News ACC 2017 More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease Yael L. Maxwell March 09, 2017